Kruit WH - Search Results

1

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response.

Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, Schmitz PI, Stoter G. Kruit WH, et al. J Clin Oncol. 1993 May;11(5):921-4. doi: 10.1200/JCO.1993.11.5.921. J Clin Oncol. 1993. PMID: 8487055

2

Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFN alpha) in metastatic melanoma.

Kruit WH, Goey SH, Monson JR, Stahel RA, Calabresi F, Mertelsmann R, Holdener EE, Eggermont AM, Bolhuis RL, de Mulder PH, et al. Kruit WH, et al. Br J Haematol. 1991 Oct;79 Suppl 1:84-6. doi: 10.1111/j.1365-2141.1991.tb08128.x. Br J Haematol. 1991. PMID: 1931717

3

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

Kruit WH, Punt CJ, Goey SH, de Mulder PH, Gratama JW, Eggermont AM, Bolhuis RL, Stoter G. Kruit WH, et al. Br J Cancer. 1996 Sep;74(6):951-5. doi: 10.1038/bjc.1996.463. Br J Cancer. 1996. PMID: 8826864 Free PMC article.

4

High-dose regimen of interleukin-2 and interferon-alpha in combination with lymphokine-activated killer cells in patients with metastatic renal cell cancer.

Kruit WH, Goey SH, Lamers CH, Gratama JW, Visser B, Schmitz PI, Eggermont AM, Bolhuis RL, Stoter G. Kruit WH, et al. J Immunother. 1997 Jul;20(4):312-20. doi: 10.1097/00002371-199707000-00008. J Immunother. 1997. PMID: 9220321 Clinical Trial.

5

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

Bouwhuis MG, Suciu S, Testori A, Kruit WH, Salès F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM. Bouwhuis MG, et al. Among authors: kruit wh. J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385998 Clinical Trial.

6

Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.

Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW. Portielje JE, et al. Among authors: kruit wh. Clin Cancer Res. 2003 Jan;9(1):76-83. Clin Cancer Res. 2003. PMID: 12538454 Clinical Trial.

7

Neuropsychiatric side effects of interferon-alfa therapy.

Van Gool AR, Kruit WH, Engels FK, Stoter G, Bannink M, Eggermont AM. Van Gool AR, et al. Among authors: kruit wh. Pharm World Sci. 2003 Feb;25(1):11-20. doi: 10.1023/a:1022449613907. Pharm World Sci. 2003. PMID: 12661471 Review.

8

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.

Van Gool AR, Verkerk R, Fekkes D, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Scharpé S, Eggermont AM, Stoter G, Hengeveld MW. Van Gool AR, et al. Among authors: kruit wh. Psychiatry Clin Neurosci. 2008 Oct;62(5):597-602. doi: 10.1111/j.1440-1819.2008.01854.x. Psychiatry Clin Neurosci. 2008. PMID: 18950381 Free article.

9

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U. Kruit WH, et al. J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715572 Clinical Trial.

10

Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients.

Van Gool AR, Van Ojik HH, Kruit WH, Mulder PG, Fekkes D, Bannink M, Scharpé S, Stoter G, Eggermont AM, Maes M, Verkerk R. Van Gool AR, et al. Among authors: kruit wh. J Interferon Cytokine Res. 2004 Jul;24(7):411-5. doi: 10.1089/1079990041535629. J Interferon Cytokine Res. 2004. PMID: 15296652

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page